My Market Wizard

Filing Category: Material Modification to Rights of Security Holders

  • VNUE, Inc. 8-K Analysis & Summary – 2/21/2025

    Analyst Summary

    • The company increased the authorized shares of the Company’s Series B Preferred Stock from 2,500 to 5,250.
    • The Board of Directors approved the amendment to the Series B Designation on February 20, 2025.

  • Aptose Biosciences Inc. 8-K Analysis & Summary – 2/21/2025

    Analyst Summary

    • Aptose Biosciences Inc. implemented a 1-for-30 reverse stock split.
    • The reverse stock split will be effective on February 26, 2025.
    • The Common Shares will trade under a new CUSIP number, 03835T408, and a new ISIN, CA03835T4081.
    • The stock will continue to trade on Nasdaq under the symbol “APTO” and on TSX under the symbol “APS.”
    • Immediately after the Reverse Stock Split becomes effective, there will be approximately 2.1 million Common Shares issued and outstanding.

    Potential Implications

    Stock Price

    • The reverse stock split is intended to increase the stock price to meet Nasdaq’s minimum listing requirements.
    • The reverse stock split could make the stock more attractive to some investors.